Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 211635
Company: NEURELIS INC
Company: NEURELIS INC
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
VALTOCO | DIAZEPAM | 5MG/SPRAY | SPRAY;NASAL | Prescription | None | Yes | No |
VALTOCO | DIAZEPAM | 7.5MG/SPRAY | SPRAY;NASAL | Prescription | None | Yes | No |
VALTOCO | DIAZEPAM | 10MG/SPRAY | SPRAY;NASAL | Prescription | None | Yes | Yes |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
01/10/2020 | ORIG-1 | Approval | Type 3 - New Dosage Form | STANDARD; Orphan |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211635s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/211635Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211635Orig1s000TOC.cfm |
Supplements
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
---|---|---|---|---|---|
12/18/2024 | SUPPL-10 | Efficacy-New Patient Population |
Letter (PDF)
|
Label is not available on this site. |
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/211635Orig1s010TAltr.pdf |
01/13/2023 | SUPPL-8 | Labeling-Package Insert, Labeling-Medication Guide |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211635s008lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/211635Orig1s008ltr.pdf | |
02/04/2022 | SUPPL-7 | Labeling-Medication Guide, Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211635s007lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/211635Orig1s007ltr.pdf | |
02/05/2021 | SUPPL-3 | Labeling-Medication Guide, Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211635s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/211635Orig1s003ltr.pdf |
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
---|---|---|---|---|---|
01/13/2023 | SUPPL-8 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211635s008lbl.pdf | |
01/13/2023 | SUPPL-8 | Labeling-Medication Guide | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211635s008lbl.pdf | |
02/04/2022 | SUPPL-7 | Labeling-Medication Guide | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211635s007lbl.pdf | |
02/04/2022 | SUPPL-7 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211635s007lbl.pdf | |
02/05/2021 | SUPPL-3 | Labeling-Medication Guide | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211635s003lbl.pdf | |
02/05/2021 | SUPPL-3 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211635s003lbl.pdf | |
01/10/2020 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211635s000lbl.pdf |